.svg)
Digital health investors operate differently than generalist VCs because they're underwriting regulatory, reimbursement, and clinical risk all at once. Many partners at these funds have backgrounds in healthcare operations, life sciences, or health policy—which means they'll probe your FDA pathway, your CPT code strategy, and your clinical evidence plan before they ask about your TAM. Come prepared to explain who pays (employer, payer, patient, provider, pharma), how you'll get paid (fee-for-service, value-based, SaaS license, risk-sharing), and what evidence you'll need to unlock each buyer. A compelling product demo matters less here than a credible answer to "what does the pilot-to-contract conversion look like at a health system?"
The bar for clinical validation has risen sharply. Investors now treat peer-reviewed outcomes data and regulatory traction as baseline requirements, not nice-to-haves. If you're pre-FDA or pre-evidence, be explicit about your timeline and budget to get there—these funds model that into their diligence. Also know that digital health sales cycles are brutal: enterprise health system deals can take 12-18 months, and many startups die in "pilot purgatory" without converting to paid contracts. The investors on this list will want to see you've thought through implementation complexity, EHR integration, and how you'll prove ROI in a buyer's specific environment. If you can show real contracted revenue (not just pilots) or letters of intent from health systems, that's worth more than growth projections.
.jpeg){kind=logo}
.png)
.jpeg)
.jpeg)
